Sökning: id:"swepub:oai:DiVA.org:umu-199833" >
Real-world Treatmen...
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
-
- Bjartell, Anders (författare)
- Lund University,Lunds universitet,Avdelningen för translationell cancerforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Division of Translational Cancer Research,Department of Laboratory Medicine,Faculty of Medicine,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital
-
- Costa, Luis (författare)
- Oncology Division, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal; Instituto de Medicina Molecular João Lobo Antunes, Lisbon, Portugal,University of Lisbon
-
- Kramer, Gero (författare)
- Department of Urology, Medical University of Vienna, Vienna, Austria
-
visa fler...
-
- Zurawski, Bogdan (författare)
- Centrum Onkologii im. Prof. F. Lukaszczyka w Bydgoszczy, Dzial Onkologii Klinicznej, Ambulatorium Chemioterapii, Bydgoszcz, Poland
-
- Galli, Luca (författare)
- Pisana University Hospital, Pisa, Italy,University Hospital of Pisa
-
- Werbrouck, Patrick (författare)
- AZ Groeninge, Kortrijk, Belgium,Algemeen Ziekenhuis Groeninge
-
- Ecke, Thorsten (författare)
- Helios Klinikum Bad Saarow, Bad Saarow, Germany
-
- Parikh, Omi (författare)
- Royal Blackburn Hospital, Blackburn, United Kingdom
-
- Bennamoun, Mostefa (författare)
- Institut Mutualiste Montsouris, Paris, France
-
- Garcia Freire, Camilo (författare)
- Hospital Clínico Universitario de Santiago, Servicio de Urología, Santiago de Compostela, Spain,Complejo Hospitalario Universitario de Santiago
-
- Peer, Avivit (författare)
- Rambam Medical Center, Haifa, Israel
-
- Ljungberg, Börje, Professor, 1949- (författare)
- Umeå University,Umeå universitet,Urologi och andrologi
-
- Cicin, Irfan (författare)
- Trakya University Hospital, Medical Oncology Department, Edirne, Turkey
-
- Smith, Emma (författare)
- Janssen-Cilag, High Wycombe, United Kingdom
-
- Lukac, Martin (författare)
- Parexel International Czech Republic sro, on behalf of Janssen Pharmaceutica NV, Beerse, Belgium
-
- Wapenaar, Robert (författare)
- Janssen-Cilag BV, Breda, Netherlands
-
- Chowdhury, Simon (författare)
- Guy's and St Thomas’ NHS Foundation Trust and Sarah Cannon Research Institute, London, United Kingdom
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2022
- 2022
- Engelska.
-
Ingår i: European Urology Open Science. - : Elsevier. - 2666-1691 .- 2666-1683. ; 45, s. 12-22
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).Objective: To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.Design, setting, and participants: A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.Intervention: Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone–radium-223 (ABI-RAD), docetaxel-abiraterone (DOCE-ABI), docetaxel-cabazitaxel (DOCE-CABA), docetaxel-enzalutamide (DOCE-ENZA), and enzalutamide-docetaxel (ENZA-DOCE).Outcome measurements and statistical analysis: Baseline patient characteristics, quality of life, mCRPC treatments, and efficacy outcomes (progression and survival) were presented descriptively.Results and limitations: Data from 727 patients were eligible for the analysis (ABI-DOCE n = 178, ABI-ENZA n = 99, ABI-RAD n = 27, DOCE-ABI n = 191, DOCE-CABA n = 74, DOCE-ENZA n = 116, and ENZA-DOCE n = 42). Demographics and disease characteristics among patients between different sequences varied greatly. Most patients who started on abiraterone or enzalutamide stopped therapy because of disease progression. No randomisation to allow treatment/sequence comparisons limited this observational study.Conclusions: The real-world PCR data complement clinical trial data, reflecting more highly selected patient populations than seen in routine clinical practice. Baseline characteristics play a role in mCRPC first-line treatment selection, but other factors, such as treatment availability, have an impact. Efficacy observations are limited and should be interpreted with caution.Patient summary: Baseline characteristics appear to have a role in the first-line treatment selection of metastatic castration-resistant prostate cancer in the real-world setting. First-line abiraterone acetate plus prednisone seems to be the preferred treatment option for older patients and those with lower Gleason scores, first-line docetaxel for younger patients and those with more advanced disease, and first-line enzalutamide for patients with fewer metastases and more favourable performance status. The benefit to patients from these observations remains unknown.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- Abiraterone acetate
- Androgen deprivation therapy
- Antiandrogen
- Cabazitaxel
- Castration-resistant prostate cancer
- Docetaxel
- Enzalutamide
- Ra-223
- Real-world evidence
- Abiraterone acetate
- Androgen deprivation therapy
- Antiandrogen
- Cabazitaxel
- Castration-resistant prostate cancer
- Docetaxel
- Enzalutamide
- Ra-223
- Real-world evidence
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Bjartell, Anders
-
Costa, Luis
-
Kramer, Gero
-
Zurawski, Bogdan
-
Galli, Luca
-
Werbrouck, Patri ...
-
visa fler...
-
Ecke, Thorsten
-
Parikh, Omi
-
Bennamoun, Moste ...
-
Garcia Freire, C ...
-
Peer, Avivit
-
Ljungberg, Börje ...
-
Cicin, Irfan
-
Smith, Emma
-
Lukac, Martin
-
Wapenaar, Robert
-
Chowdhury, Simon
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
European Urology ...
- Av lärosätet
-
Umeå universitet
-
Lunds universitet